insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

Leukemia & lymphoma 2026 p. 1-8

Hu L, Lu B, Wei X, Wang Y, Xie M, Li J, Feng C, Li G, Qiu X, Zhang J, Guo X, Zhong Z, Li X, Zhang Q, Zhou J

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

We conducted a retrospective, multi-center, real-world study to evaluate efficacy and safety of zanubrutinib combination therapy as first-line treatment for diffuse large B-cell lymphoma (DLBCL) betwe

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Hu L, Lu B, et al. (2026). A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.. Leukemia & lymphoma, 1-8. https://doi.org/10.1080/10428194.2026.2654977
MLA Hu L, et al.. "A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.." Leukemia & lymphoma, 2026, pp. 1-8.
PMID 42027122
DOI 10.1080/10428194.2026.2654977

Abstract

We conducted a retrospective, multi-center, real-world study to evaluate efficacy and safety of zanubrutinib combination therapy as first-line treatment for diffuse large B-cell lymphoma (DLBCL) between August 2020 and August 2025. Patients received RCHOP as standard therapy, while those with central nervous system (CNS) involvement were treated with R plus high-dose methotrexate (R + HD-MTX). Seventy patients were enrolled: 53 (75.7%) received RCHOP and17 (24.3%) received R + HD-MTX. The complete response rate (CRR) was 88.6% and the overall response rate (ORR) was 92.9%. The estimated 2-year progression-free survival (PFS) rate was 79.3% and the estimated 2-year overall survival (OS) rate was 98.1%. The estimated 2-year PFS was significantly higher in MCD (MYD88/CD79B) subtype than non-MCD subtype (100% vs. 70.1%,  = 0.011). No treatment-related deaths were reported. Zanubrutinib combination therapy showed favorable efficacy in first-line DLBCL, particularly in BTK inhibitor-sensitive patients, with a manageable safety profile and low rates of severe adverse events.

같은 제1저자의 인용 많은 논문 (5)